ID   MG63.3
AC   CVCL_WL01
DR   GEO; GSM1915000
DR   GEO; GSM1915001
DR   GEO; GSM1915002
DR   GEO; GSM1915003
DR   GEO; GSM1915030
DR   GEO; GSM1915031
DR   GEO; GSM1915032
DR   GEO; GSM2635313
DR   GEO; GSM2635314
DR   Wikidata; Q95989262
RX   PubMed=26320182;
RX   PubMed=29334376;
CC   Population: Caucasian.
CC   Characteristics: Has a high metastatic potential.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Omics: H3K4me1 ChIP-seq epigenome analysis.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Bone, left femur; UBERON=UBERON_0000981.
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_R705 ! MG63.2
SX   Male
AG   14Y
CA   Cancer cell line
DT   Created: 24-05-19; Last updated: 29-06-23; Version: 8
//
RX   PubMed=26320182; DOI=10.18632/oncotarget.5177;
RA   Ren L., Mendoza A., Zhu J., Briggs J.W., Halsey C., Hong E.S.,
RA   Burkett S.S., Morrow J.J., Lizardo M.M., Osborne T., Li S.Q.,
RA   Luu H.H., Meltzer P.S., Khanna C.;
RT   "Characterization of the metastatic phenotype of a panel of
RT   established osteosarcoma cells.";
RL   Oncotarget 6:29469-29481(2015).
//
RX   PubMed=29334376; DOI=10.1038/nm.4475;
RA   Morrow J.J., Bayles I., Funnell A.P.W., Miller T.E., Saiakhova A.,
RA   Lizardo M.M., Bartels C.F., Kapteijn M.Y., Hung S., Mendoza A.,
RA   Dhillon G., Chee D.R., Myers J.T., Allen F., Gambarotti M., Righi A.,
RA   DiFeo A., Rubin B.P., Huang A.Y., Meltzer P.S., Helman L.J., Picci P.,
RA   Versteeg H., Stamatoyannopoulos J.A., Khanna C., Scacheri P.C.;
RT   "Positively selected enhancer elements endow osteosarcoma cells with
RT   metastatic competence.";
RL   Nat. Med. 24:176-185(2018).
//